Key Stats for Illumina Stock
- Current Price: $206.45
- Target Price (Mid): ~$268
- Street Target: ~$203
- Potential Total Return: ~30%
- Annualized IRR: ~6% / year
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free) >>>
What Happened?
Illumina (ILMN) is about to complete one of the stranger round trips in large-cap health care. On September 21, the gene-sequencing company rejoins the S&P 500, roughly 27 months after S&P Dow Jones Indices dropped it from the benchmark on June 24, 2024, the same day it finished spinning off the cancer-test maker GRAIL and watched GoDaddy take its seat. The stock that got demoted to the mid-cap index near its lows is coming back up 57% from its 2025 close, trading at $206.45 and sitting about 11% below its 52-week high of $231.81.
The business is clearly healthier than when the index dropped it, but the price already reflects much of the repair. Illumina trades near 38 times trailing earnings, a fat premium to the market and most peers, and the readmission brings mechanical index buying that says nothing about fundamentals. The honest question is whether enough of it is still ahead of the stock rather than behind it.
The Business That Earned Its Way Back In
Index membership follows performance, and the performance is genuine. In the second quarter, reported July 30, Illumina posted revenue of $1.16 billion, up 9.5% year over year and ahead of the roughly $1.13 billion expected. Non-GAAP EPS of $1.31 rose about 10% and beat the $1.23 consensus, at least its fifth straight beat. Management raised full-year guidance to $4.60 billion to $4.64 billion in revenue and $5.30 to $5.40 in EPS, roughly 11% higher at the midpoint.
The engine is the clinical business, now about 65% of sequencing consumables revenue. Clinical consumables grew 15% excluding China, with the U.S. and Canada above 20%, though that 15% is a step down from roughly 20% the prior quarter, as the Middle East and Latin America softened. Driving it is a fast-growing base of NovaSeq X instruments, the flagship high-throughput sequencer, with more than 95 placed in the quarter, well above the 50-to-60 pace management set 18 months ago. Each placement seeds years of recurring demand. CEO Jacob Thaysen pushed back on the fear that clinical growth falls off a cliff once customers leave older machines: “It’s a wave, and we are surfing it,” he told analysts, casting elevated placements as customers building capacity for volume they can already see. That distinction is the 2027 case, separating a one-time transition bump from a durable ramp.
A quieter point from the call may matter more to the premium than the beat. CFO Ankur Dhingra noted that Illumina’s instruments avoid the GPU architecture, now pushing memory and compute costs higher across hardware makers, a structural cost edge as it scales new products. Even so, the weights are real: research and applied consumables fell 7% on cautious U.S. academic funding, and China stays a drag with Illumina on its “unreliable entity” list. The company still held a non-GAAP operating margin at 22.5%, above guidance.
See historical and forward estimates for Illumina stock (It’s free!) >>>
What $206 Already Assumes
Illumina trades near 38 times trailing and 36 times forward earnings, against roughly 23 times for Thermo Fisher Scientific and 22 for Agilent Technologies, two larger, more diversified peers growing at least as fast. On forward EV/EBITDA, its 22.9 times tops Thermo’s 20.4 and Agilent’s 18.1. That P/E premium is not obviously unearned, given a near-monopoly in sequencing and high-margin recurring revenue, but it prices the stock as if clinical acceleration continues and margins keep climbing.
The mean target sits at $202.65, essentially at the current price, a sign the market thinks price and fair value have converged. Coverage splits 7 buys, and 4 outperforms against 6 holds, 3 underperforms, and 1 sell, so a cautious minority persists after the run. Bulls got louder after Q2, with Argus upgrading to buy at $235, JPMorgan moving to $230, and Stifel, Piper Sandler, and Guggenheim near $225. Insiders leaned the other way: director Keith Meister sold about $57 million of stock through his Corvex Management funds in early September, at roughly $213 to $221.
See how Illumina performs against its peers in TIKR (It’s free!) >>>
TIKR Advanced Model Analysis
- Current Price: $206.45
- Target Price (Mid): ~$268 (by end of 2030)
- Potential Total Return: ~30%
- Annualized IRR: ~6% / year
See analysts’ growth forecasts and price targets for Illumina stock (It’s free!) >>>
Two drivers carry the revenue line. The first is clinical sequencing consumables, compounding in the mid-teens as the larger NovaSeq X base converts placements into recurring pull-through. The second is the multiomics and data portfolio, including SomaLogic proteomics and early BioInsight revenue, which management expects to add 1 to 2 points of growth from 2027. Together, they support a mid-case revenue CAGR near 6%. The margin driver is operating leverage: as a higher-margin consumables mix up against a fixed cost base, net margin moves toward roughly 23% and lifts EPS growth to around 10% a year on mid-single-digit revenue growth.
The primary risk is the multiple. At 38 times earnings, the stock has no cushion, so any slip in clinical growth, a longer research downturn, or a China escalation could compress the P/E faster than earnings grow. In the upside case, volumes and new products beat, margins run higher, and the return tracks the model’s high-case path well above the mid-case target. In the downside case, the premium unwinds toward peer multiples, and the stock stays flat while earnings rise into the valuation.
Conclusion
The clearest test comes at third-quarter results, expected in late October, though the date is not yet confirmed. Management guided to about 4.5% Rest of World organic growth, a step down from Q2’s 8.1% that executives put down to seasonality and tougher instrument comparisons, alongside EPS of $1.33 to $1.38. What decides the thesis is not headline EPS but clinical consumables growth. Hold it in the mid-teens, and the wave Thaysen described is real, and the premium survives. Let it slip toward high single digits, and the market starts asking whether it paid for a ramp that is already fading. Index membership pads the shareholder base on September 21.
See what stocks billionaire investors are buying so you can follow the smart money with TIKR.
Should You Invest in Illumina?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Illumina, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Illumina alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze Illumina on TIKR Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
